France-based medtech company Defymed said today that it’s developing a novel insulin delivery device which it hopes to bring to market by the end of 2020. The company’s device, ExOlin, uses a biocompatible membrane that is nonbiodegradable and permeable to insulin, according to Defymed. The insulin delivery device is designed to be implanted into a […]
Research & Development
Medtech stories we missed this week: July 7, 2017
From EnvisionTEC’s FDA approval to InVivo Therapeutics adding a new clinical site, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. EnvisionTEC wins FDA nod for 3D printing E-Denture material EnvisionTEC announced in a June 30 press release that it has received FDA approval for its E-Denture material […]
Capillary Biomedical takes aim at ‘the Achilles heel of diabetes’
Major players in the medical device realm are in a heated race to develop the first artificial pancreas to help patients with diabetes manage the chronic condition. Just last year, Medtronic (NYSE:MDT) won FDA approval for its MiniMed 670G hybrid-closed loop system. But while companies compete for the top spot in developing what could be a […]
Researchers develop light-sensitive hydrogel for drug delivery
Researchers at the Hong Kong University of Science and Technology have developed a light-sensitive hydrogel that could be useful for drug delivery. Conventional materials for hydrogel scaffolds include synthetic polymers or natural biomolecules. This leaves the material to exist as a passive scaffold that can’t interact with the signals involved in biological processes. Instead, this […]
Google backs Decibel Therapeutics in big data hearing loss play
Decibel Therapeutics said today it landed an investment from GV, formerly Google Ventures. GV agreed to make an equity investment in the Boston-based company and lend its capabilities in big data sciences and analytics to Decibel’s efforts in developing therapies for hearing loss and tinnitus. “We are delighted to work with GV to amplify our […]
Eli Lilly pledges up to $52m to Purdue for improving injection tech
Eli Lilly (NYSE:LLY) said today that it pledged up to $52 million to Purdue University as part of a 5-year research agreement. The deal is Purdue’s largest strategic collaboration with a single company, according to the university. The group is slated to focus on improving the delivery of injectable medications with the goals of reducing pain and […]
‘Nanolock’ could help diagnose and treat cancer with individualized therapies
In a study published in ACS Sensors, a team of researchers described how they develop a method to recognize a particular mutation in the genetic code of a cancerous cell. If cancers are caught early enough in the cell mutation process, many of them can be stopped with chemotherapy and other forms of treatment. This new […]
Medtech stories we missed this week: June 30, 2017
From ConforMIS touting its knee replacement study to Consulting Radiologists’s new breast cancer detection tool, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Study: Low-dose CT scanning improves Ankylosing Spondylitis assessment A new study has shown that low-dose computed tomography (LD-CT) is more sensitive than X-rays for monitoring […]
Researchers develop molecular cage for drug delivery
Researchers from Trinity College Dublin have created a molecular cage that can house different molecules for drug-delivery applications. The cage’s hollow structure, made up of sub-cages, enables researchers to load different molecules and design them to react only when the cages are surrounded by particular environments. The team’s work was published in Nature Communications. “We have […]
Dissolvable microneedle patch for flu vaccine succeeds in Phase I
Dissolvable microneedle patches that deliver the flu vaccine could provide a safe and cost-effective alternative to traditional immunization methods, according to the results from a Phase I trial published in The Lancet this week. The study enrolled adults ages 18 to 49 and randomly assigned them to receive a single dose of inactivated flu vaccine via […]
